A5048635112- Lung Cancer Diagnosis and Treatment
- Renal cell carcinoma treatment
- Lung Cancer Treatments and Mutations
- Gastric Cancer Management and Outcomes
- Cancer Immunotherapy and Biomarkers
- Global Healthcare and Medical Tourism
- Cardiac Valve Diseases and Treatments
- Cancer Genomics and Diagnostics
- Pancreatic and Hepatic Oncology Research
- Aortic Disease and Treatment Approaches
- Economic and Financial Impacts of Cancer
- Climate Change and Health Impacts
- Muscle and Compartmental Disorders
- Radiopharmaceutical Chemistry and Applications
- Agriculture Sustainability and Environmental Impact
- Infective Endocarditis Diagnosis and Management
- Renal and related cancers
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Noise Effects and Management
- Global Cancer Incidence and Screening
- Esophageal Cancer Research and Treatment
- Multiple and Secondary Primary Cancers
- Health Systems, Economic Evaluations, Quality of Life
- Air Quality and Health Impacts
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Case Western Reserve University
2022-2025
University School
2022-2025
Cleveland Clinic
2023
Urban environments contribute substantially to the rising burden of cardiometabolic diseases worldwide. Cities are complex adaptive systems that continually exchange resources, shaping exposures relevant human health such as air pollution, noise, and chemical exposures. In addition, urban infrastructure provisioning influence multiple domains risk, including behaviors, psychological stress, nutrition through various pathways (eg, physical inactivity, heat food systems, availability green...
Background An immune checkpoint inhibitor (ICI) backbone is a standard of care for frontline metastatic clear cell renal carcinoma, involving either ICI doublet or tyrosine kinase (TKI) with ICI. These phase 3 trials used sunitinib control arm. The optimal regimen uncertain. Objective To compare long-term responders these using extended follow-up data stratified by International Metastatic RCC Database Consortium risk group. Methods Phase trial (CheckMate 214, KEYNOTE-426, CheckMate 9ER, and...
448 Background: We investigated access to ICIs in patients (pts) randomized the control arm across positive phase 3 trials for renal cell carcinoma (RCC) and urothelial (UC) with an ICI-based regimen. Methods: A search of clinicaltrials.gov was performed October 2024 including, “renal carcinoma” OR “urothelial cancer”, “immune”, “phase 3”, producing 64 results. These were limited investigational containing ICI therapy without arm, no cross over initial trial design, demonstrated overall...
8067 Background: The PACIFIC trial established concurrent chemoradiotherapy (CCRT) followed by consolidation durvalumab as standard of care for unresectable stage III non-small cell lung cancer (NSCLC). This study showed a progression free survival (PFS) 16.9 mo and an overall (OS) 47.5 mo. There is paucity real world data with PACIFIC, especially in diverse patient populations. We present outcomes the regimen NCI-designated comprehensive center (CCC) racially diverse, high poverty catchment...
The urgent call for a 'great food transformation'Unhealthy consumption linked to unsustainable systems is the major determinant of human and planetary health, accounting nearly 12 million premature deaths each year third greenhouse gas (GHG) emissions.Dominant choices demand are driving biodiversity loss, water scarcity, overuse pesticides, nutrient pollution, climate change, excessive use antibiotics.Injustices inequities embedded within an increasingly fragile system have multiplied all...
Platelet counts in reactive thrombocytosis rarely exceed 1000 × 10
8588 Background: Small cell lung cancer (SCLC) comprises 10-15% of all cancers yet little is known about the impact social determinants health (SDOH) on outcomes in patients with SCLC. This study aims to assess various SDOH overall survival (OS) diagnosed SCLC at a single institution. Methods: We have established large clinical/pathologic/genomic database and treated for between 1998-2022 our institution retrospective study. Demographic data including sex, race, age, stage, address, smoking...
e24203 Background: The COVID-19 pandemic altered cancer care delivery, notably through a rise in telemedicine. Patients of racial minority, low income, or older age are less likely to engage virtual platforms. Support services effective ways combat negative effects both diagnosis and pandemic. However, research is limited regarding the impact on support-based organizations. We aimed identify variations participant demographics resource utilization at Gathering Place (TGP), support community,...
"HSR23-090: Racial Differences in Outcomes of Osimertinib Patients With EGFR-Positive Non–Small Cell Lung Cancer a Real World US Population" published on 31 Mar 2023 by National Comprehensive Network.